On STAT's podcast, hear about what happened with AbbVie's schizophrenia drug, Amgen's obesity drug and what might happen at ...
Amgen addresses safety concerns for its weight loss drug MariTide after new data suggests a potential 4% reduction in bone ...
In this photo illustration, Amgen logo is displayed on a smartphone with a S&P ... [+] index website background. (Photo ...
Amgen has rebuffed claims made by an analyst suggesting that its obesity drug MariTide is associated with reductions in bone ...
a tiny shred of data on Amgen’s lead obesity candidate — not yet verified — erased $12 billion in market value. The data, ...
The tab contains data on bone density changes in patients who received Amgen’s obesity prospect MariTide in a phase 1 ...
Amgen (AMGN) issued the following statement on the MariTide Phase 1 data. “As previously stated, Amgen does not see an association ...
An analyst note raising questions about Amgen’s MariTide triggered a stock sell-off Tuesday. Elsewhere, Roche and Novartis ...
Amgen on Wednesday sought to allay concerns that its MariTide, investigational weight-loss shot could be linked to a loss of bone mineral density. Amgen shares fell more than 7% on Tuesday after ...
Amgen stock rebounded Wednesday, shaking off "overdone" fears that its monthly weight-loss shot, MariTide, causes excessive bone mineral density loss. Please watch the video at Investors.com - How ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback